secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIGAND PHARMACEUTICALS INC (LGND)
CIK:        0000886163
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0000886163-26-000030
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ligand Q1 royalty revenue +56% to $43M; reaffirms raised guidance amid XOMA acquisition
--------------------------------------------------------------------------------

- Q1 royalty revenue $43.0M (+56% YoY); total revenue $51.7M (+14%).
- GAAP net loss $13.3M ($0.67/sh) vs loss $42.5M ($2.21/sh) prior yr; adj EPS $1.63 (+23%).
- Reaffirms FY2026 guidance: royalty rev $225-250M, total rev $270-310M, adj EPS $8.50-9.50.
- Acquiring XOMA for $39/share in cash + CVR; adds over 120 assets incl. Vabysmo, Ojemda, Miplyffa.
- Cash and investments $779.4M at Mar 31; deal expected to close Q3 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886163/000088616326000030/0000886163-26-000030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886163/000088616326000030/lgnd-20260507.htm
  HTML page:      https://secwatch.observer/filing/0000886163-26-000030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer